0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      3Rs implementation in veterinary vaccine batch-release testing: Current state-of-the-art and future opportunities. A webinar and workshop report.

      1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 7 , 14 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 18 , 5 , 11
      Biologicals : journal of the International Association of Biological Standardization
      Elsevier BV
      3Rs, Batch-release testing, Biologicals, Non-animal testing, Quality control, Vaccines

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Regulatory authorities require veterinary batch-release testing to confirm vaccine potency and safety, but these tests have traditionally relied on large numbers of laboratory animals. Advances in vaccine research and development offer increasing opportunities to replace in vivo testing, and some stakeholders have made significant progress in incorporating 3Rs elements in quality control strategies. A three-part event series entitled "3Rs Implementation in Veterinary Vaccine Batch-Release Testing: Current state-of-the-art and future opportunities" was jointly organized by the Animal-Free Safety Assessment Collaboration, HealthforAnimals, and the International Alliance of Biological Standardization. Two webinars and a workshop aimed to outline the state-of-the-art non-animal approaches for veterinary batch-release testing. The events included information on the state of the deletion of obsolete safety testing and the current initiatives implemented by European, North American, and Asian-Pacific stakeholders on 3Rs implementation and regulatory acceptance. The events contributed to a better understanding of the barriers to 3Rs implementation. Participants highlighted the need for open communication, continued collaboration between stakeholders, and international harmonization of regulatory requirements to help accelerate acceptance. Despite the challenges, the countries represented at this three-part event have shared their commitments to advancing the acceptance of alternative methods.

          Related collections

          Author and article information

          Journal
          Biologicals
          Biologicals : journal of the International Association of Biological Standardization
          Elsevier BV
          1095-8320
          1045-1056
          Aug 2023
          : 83
          Affiliations
          [1 ] SciethiQ, under contract with Humane Society International, Basel, Switzerland. Electronic address: lviviani@sciethiq.com.
          [2 ] Paul-Ehrlich-Institut, Langen, Germany; European Medicines Agency (EMA), Brussels, Belgium.
          [3 ] European Medicines Agency (EMA), Brussels, Belgium; Belgian Federal Agency for Medicines and Health Products (FAMPH), Brussels, Belgium.
          [4 ] Subject Matter Expert at European and British Pharmacopoeia, London, United Kingdom.
          [5 ] HealthforAnimals, Brussels, Belgium.
          [6 ] Agence Nationale de Sécurité Sanitaire de l'alimentation, de l'environnement et du Travail (French Agency for Food, Environmental and Occupational Health & Safety), ANSES-Nancy, France.
          [7 ] Ministry of Agriculture of Indonesia, Jakarta, Indonesia.
          [8 ] MSD Animal Health, Milton Keynes, UK.
          [9 ] MSD Animal Health, New Jersey, USA.
          [10 ] AnimalhealthEurope, Brussels, Belgium.
          [11 ] International Alliance for Biological Standardization Europe (IABS), Geneva, Switzerland.
          [12 ] Indian Pharmacopoeia Commission, Ghaziabad, India.
          [13 ] MSD Animal Health, Boxmeer, the Netherlands.
          [14 ] European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, Strasbourg, France.
          [15 ] P95 Epidemiology & Pharmacovigilance, Leuven, Belgium.
          [16 ] Ceva, Budapest, Hungary.
          [17 ] MSD Animal Health (MSD AH), Pune, India.
          [18 ] US Department of Agriculture (USDA)- APHIS, Riverdale, MD, USA.
          [19 ] Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK; National Institute for Biological Standards and Control (NIBSC), Potters Bar, Hertfordshire, UK.
          [20 ] Zoetis Inc, Leatherhead, UK.
          [21 ] AsianAnimalHealth, Tannery Road #10-01, HB Centre 1, Singapore.
          [22 ] World Organization for Animal Health, Paris, France.
          [23 ] Zoetis Belgium SA, Ottignies-Louvain-la-Neuve, Belgium.
          [24 ] Australian Pesticides and Veterinary Medicines Authority, Sydney, Australia.
          Article
          S1045-1056(23)00033-7
          10.1016/j.biologicals.2023.101695
          37516084
          390075b3-6972-4ea4-b3a2-fb11dceac0e5
          History

          Biologicals,3Rs,Non-animal testing,Quality control,Vaccines,Batch-release testing

          Comments

          Comment on this article